The first randomized control trial of the school-based intervention called Supporting Transition Resilience of Newcomer Groups (STRONG) shows significant reductions in depression, anxiety and behavior ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101. Beyond its mental health applications, NRX-101 shows promise as a non-opioid ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.